Grace Therapeutics (GRCE) Liabilities and Shareholders Equity (2017 - 2026)

Grace Therapeutics has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $66.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 7.42% year-over-year to $66.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $271.5 million (up 1.21% YoY) and the FY2026 annual result came in at $66.7 million, down 7.42% from the prior year.
• Liabilities and Shareholders Equity eased to $66.7 million in Q1 2026 per GRCE's latest filing, from $68.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $128.6 million in Q1 2022 and troughed at $61.2 million in Q4 2024.
• A 5-year average of $83.0 million and a median of $73.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 106.66% in 2022, then plunged 41.54% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $116.8 million in 2022, then plunged by 34.77% to $76.2 million in 2023, then declined by 19.64% to $61.2 million in 2024, then advanced by 11.86% to $68.5 million in 2025, then fell by 2.68% to $66.7 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $66.7 million, $68.5 million, and $66.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.